MX2023010449A - Composiciones y métodos para tratar la policitemia. - Google Patents
Composiciones y métodos para tratar la policitemia.Info
- Publication number
- MX2023010449A MX2023010449A MX2023010449A MX2023010449A MX2023010449A MX 2023010449 A MX2023010449 A MX 2023010449A MX 2023010449 A MX2023010449 A MX 2023010449A MX 2023010449 A MX2023010449 A MX 2023010449A MX 2023010449 A MX2023010449 A MX 2023010449A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treating polycythemia
- polycythemia
- treating
- Prior art date
Links
- 208000008601 Polycythemia Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160412P | 2021-03-12 | 2021-03-12 | |
| US202163185464P | 2021-05-07 | 2021-05-07 | |
| PCT/US2022/020038 WO2022192730A1 (en) | 2021-03-12 | 2022-03-11 | Compositions and methods for treating polycythemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010449A true MX2023010449A (es) | 2023-11-09 |
Family
ID=83228388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010449A MX2023010449A (es) | 2021-03-12 | 2022-03-11 | Composiciones y métodos para tratar la policitemia. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20260027107A1 (enExample) |
| EP (1) | EP4304596A4 (enExample) |
| JP (1) | JP2024509265A (enExample) |
| KR (1) | KR20230169981A (enExample) |
| AU (1) | AU2022233178A1 (enExample) |
| BR (1) | BR112023018403A2 (enExample) |
| CA (1) | CA3213395A1 (enExample) |
| IL (1) | IL305806A (enExample) |
| MX (1) | MX2023010449A (enExample) |
| WO (1) | WO2022192730A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230169981A (ko) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | 적혈구증가증을 치료하기 위한 조성물 및 방법 |
| CN116942668A (zh) * | 2023-03-17 | 2023-10-27 | 天津医科大学 | Glyt1抑制剂在治疗器官纤维化中的应用 |
| WO2025059425A1 (en) * | 2023-09-15 | 2025-03-20 | Disc Medicine, Inc. | Glyt-1 inhibitors and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| KR20230169981A (ko) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | 적혈구증가증을 치료하기 위한 조성물 및 방법 |
-
2022
- 2022-03-11 KR KR1020237034671A patent/KR20230169981A/ko active Pending
- 2022-03-11 AU AU2022233178A patent/AU2022233178A1/en active Pending
- 2022-03-11 WO PCT/US2022/020038 patent/WO2022192730A1/en not_active Ceased
- 2022-03-11 JP JP2023555275A patent/JP2024509265A/ja active Pending
- 2022-03-11 MX MX2023010449A patent/MX2023010449A/es unknown
- 2022-03-11 BR BR112023018403A patent/BR112023018403A2/pt unknown
- 2022-03-11 CA CA3213395A patent/CA3213395A1/en active Pending
- 2022-03-11 EP EP22768132.7A patent/EP4304596A4/en active Pending
- 2022-03-11 US US18/280,837 patent/US20260027107A1/en active Pending
- 2022-03-11 IL IL305806A patent/IL305806A/en unknown
-
2024
- 2024-03-05 US US18/596,341 patent/US20240269132A1/en not_active Abandoned
- 2024-10-23 US US18/923,904 patent/US20250248995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250248995A1 (en) | 2025-08-07 |
| KR20230169981A (ko) | 2023-12-18 |
| BR112023018403A2 (pt) | 2023-10-10 |
| JP2024509265A (ja) | 2024-02-29 |
| IL305806A (en) | 2023-11-01 |
| EP4304596A1 (en) | 2024-01-17 |
| CA3213395A1 (en) | 2022-09-15 |
| EP4304596A4 (en) | 2025-02-19 |
| WO2022192730A1 (en) | 2022-09-15 |
| AU2022233178A1 (en) | 2023-10-26 |
| US20240269132A1 (en) | 2024-08-15 |
| US20260027107A1 (en) | 2026-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500329A1 (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| PH12022550399A1 (en) | MTA-Cooperative PRMT5 Inhibitors | |
| MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| JOP20200122A1 (ar) | مركبات مفيدة لتثبيط cdk7 | |
| MX2024005855A (es) | Procedimientos para tratar el cancer. | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| EA201490673A1 (ru) | Производные пирролопиримидина и пурина | |
| TN2015000121A1 (en) | Gdf-8 inhibitors | |
| PH12020551934A1 (en) | Magl inhibitors | |
| GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| UA91560C2 (ru) | Соединения ряда изоиндолимидов, их композиция и применение | |
| BR112023018403A2 (pt) | Composições e métodos para tratar policitemia | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| MX2023010477A (es) | Composiciones y metodos para tratar la anemia asociada con un trastorno ribosomico. | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
| MX2024015057A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa-1 y composiciones farmaceuticas que los comprenden | |
| PH12021550093A1 (en) | Compounds for use in the treatment of fascioliasis | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
| MX2019008847A (es) | Profarmacos de cisteamina. | |
| PH12021550323A1 (en) | Dendrimer formulations |